CN107058171B - 具有降低胆固醇降低甘油三酯作用的戊糖乳杆菌及应用 - Google Patents
具有降低胆固醇降低甘油三酯作用的戊糖乳杆菌及应用 Download PDFInfo
- Publication number
- CN107058171B CN107058171B CN201710091198.2A CN201710091198A CN107058171B CN 107058171 B CN107058171 B CN 107058171B CN 201710091198 A CN201710091198 A CN 201710091198A CN 107058171 B CN107058171 B CN 107058171B
- Authority
- CN
- China
- Prior art keywords
- cholesterol
- strain
- triglyceride
- lactobacillus pentosus
- pentosus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title claims abstract description 95
- 235000012000 cholesterol Nutrition 0.000 title claims abstract description 46
- 241000186684 Lactobacillus pentosus Species 0.000 title claims abstract description 27
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 title abstract description 30
- 230000001603 reducing effect Effects 0.000 title abstract description 29
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 7
- 235000013376 functional food Nutrition 0.000 claims abstract description 5
- 238000004321 preservation Methods 0.000 claims abstract description 5
- 238000002360 preparation method Methods 0.000 claims description 6
- 150000002632 lipids Chemical class 0.000 claims description 5
- 238000009629 microbiological culture Methods 0.000 claims description 3
- 238000012360 testing method Methods 0.000 abstract description 21
- 230000000694 effects Effects 0.000 abstract description 19
- 239000002253 acid Substances 0.000 abstract description 9
- 239000003814 drug Substances 0.000 abstract description 7
- 230000006870 function Effects 0.000 abstract description 5
- 231100000331 toxic Toxicity 0.000 abstract description 5
- 230000002588 toxic effect Effects 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 3
- 229940099352 cholate Drugs 0.000 abstract description 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 abstract description 2
- 238000001727 in vivo Methods 0.000 abstract description 2
- 239000003833 bile salt Substances 0.000 description 14
- 239000001963 growth medium Substances 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 230000001580 bacterial effect Effects 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 231100000820 toxicity test Toxicity 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 108020004465 16S ribosomal RNA Proteins 0.000 description 5
- 108010000912 Egg Proteins Proteins 0.000 description 5
- 102000002322 Egg Proteins Human genes 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 235000013345 egg yolk Nutrition 0.000 description 5
- 210000002969 egg yolk Anatomy 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 238000009630 liquid culture Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- -1 phospho-sulfur-iron Chemical compound 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 238000003794 Gram staining Methods 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 241000186660 Lactobacillus Species 0.000 description 3
- 230000003385 bacteriostatic effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000004737 colorimetric analysis Methods 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 229940039696 lactobacillus Drugs 0.000 description 3
- 239000008223 sterile water Substances 0.000 description 3
- KEQXNNJHMWSZHK-UHFFFAOYSA-L 1,3,2,4$l^{2}-dioxathiaplumbetane 2,2-dioxide Chemical compound [Pb+2].[O-]S([O-])(=O)=O KEQXNNJHMWSZHK-UHFFFAOYSA-L 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000016938 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- WNBCMONIPIJTSB-BGNCJLHMSA-N Cichoriin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1c(O)cc2c(OC(=O)C=C2)c1 WNBCMONIPIJTSB-BGNCJLHMSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010039020 Rhabdomyolysis Diseases 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- YBCFASPYBHNQOC-UHFFFAOYSA-N [P].[S].[Fe] Chemical compound [P].[S].[Fe] YBCFASPYBHNQOC-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N aldehydo-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940093496 esculin Drugs 0.000 description 2
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 2
- AWRMZKLXZLNBBK-UHFFFAOYSA-N esculin Natural products OC1OC(COc2cc3C=CC(=O)Oc3cc2O)C(O)C(O)C1O AWRMZKLXZLNBBK-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000003736 gastrointestinal content Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 230000015784 hyperosmotic salinity response Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000004899 motility Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102100032252 Antizyme inhibitor 2 Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 101000798222 Homo sapiens Antizyme inhibitor 2 Proteins 0.000 description 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108010048581 Lysine decarboxylase Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical class OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 102000052812 Ornithine decarboxylases Human genes 0.000 description 1
- 108700005126 Ornithine decarboxylases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 244000057717 Streptococcus lactis Species 0.000 description 1
- 235000014897 Streptococcus lactis Nutrition 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- 108010069201 VLDL Cholesterol Proteins 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 229940089837 amygdalin Drugs 0.000 description 1
- YZLOSXFCSIDECK-UHFFFAOYSA-N amygdalin Natural products OCC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC(C#N)c3ccccc3 YZLOSXFCSIDECK-UHFFFAOYSA-N 0.000 description 1
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- YWGDOWXRIALTES-NRFANRHFSA-N bepotastine Chemical compound C1CN(CCCC(=O)O)CCC1O[C@H](C=1N=CC=CC=1)C1=CC=C(Cl)C=C1 YWGDOWXRIALTES-NRFANRHFSA-N 0.000 description 1
- 229960002071 bepotastine Drugs 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- YGHHWSRCTPQFFC-UHFFFAOYSA-N eucalyptosin A Natural products OC1C(O)C(O)C(CO)OC1OC1C(OC(C#N)C=2C=CC=CC=2)OC(CO)C(O)C1O YGHHWSRCTPQFFC-UHFFFAOYSA-N 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 229910000398 iron phosphate Inorganic materials 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- WBJZTOZJJYAKHQ-UHFFFAOYSA-K iron(3+) phosphate Chemical compound [Fe+3].[O-]P([O-])([O-])=O WBJZTOZJJYAKHQ-UHFFFAOYSA-K 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 229940072205 lactobacillus plantarum Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000006395 oxidase reaction Methods 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/167—Pentosus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明公开了一株从甘肃玛曲县藏獒肠道中分离纯化出的具有降胆固醇、降甘油三酯作用的戊糖乳杆菌(La.Pentosus),保藏号为CGMCC 7426,试验证明,菌株具有很强的耐酸、耐胆盐能力,可显著降低胆固醇(TC),并可降低甘油三酯(TG),小鼠体内试验发现,该菌株无任何毒副作用,因此,本发明菌株可用于降脂降胆固醇保健药品及功能食品的制备。
Description
【技术领域】
本发明涉及一种戊糖乳杆菌,特别是一种具有降胆固醇降甘油三酯作用的戊糖乳杆菌(La.Pentosus)及其应用。
【背景技术】
胆固醇是人体必需的营养成分,在体内承担着重要的生理功能,然而人体血清中胆固醇含量往往过高,血清胆固醇过高所造成的一系列心血管疾病普遍存在。现代研究已发现,动脉粥样硬化、静脉血栓形成与高胆固醇血症有密切的相关性。WTO曾预测,到2030年心血管疾病将是导致死亡的主要原因,影响着全世界大约2.36亿人们的健康。曾有报道,西欧国家和东欧国家的心脏病发生率是由于血胆脂醇过多造成的。与正常血脂水平人群相比,高血脂人群具有高出3倍的心脏病诱发风险。甘油三酯(Triglyceride,缩写TG)是长链脂肪酸和甘油形成的脂肪分子,是人体内含量最多的脂类,大部分组织均可以利用甘油三酯分解产物供给能量。但如果甘油三酯过量,囤积于皮下就会使身体肥胖,囤积于血管壁则造成动脉硬化,囤积于心脏就会导致心脏肥大,囤积于肝脏则会造成脂肪肝。目前我国有近1/3的成年人的血脂偏高,高血脂症现在已成为人类健康的第一隐形杀手。随着社会的进步,人们健康意识的增强,减肥降脂迫在眉睫。
目前,主要通过他汀类药物控制高血脂症,其能竞争性抑制HMG-CoA还原酶(胆固醇合成的限速酶)的活性减少胆固醇的自体合成,特异性降低血清胆固醇(总胆固醇TC、低密度脂蛋白胆固醇LDL和极低密度脂蛋白胆固醇VLDL),中度降低甘油三酯水平和升高高密度脂蛋白水平,由此对动脉粥样硬化和冠心病的防治产生作用。但该种药物具有严重的毒副作用,容易造成肌痛、头痛、胃肠不适、血脂紊乱、肝肾功能损害等副作用。他汀类药物的一种较严重的不良反应是横纹肌溶解。西立伐他汀(拜斯亭)由于严重的致横纹肌溶解及肾衰竭,于2001年8月在世界范围内收回,它已导致美国及欧洲部分地区52例病人死亡的事故。因此,开发和利用具有减肥降脂作用,且无毒无害的保健药品,对保护人体健康具有重要的现实意义。
益生菌作为“有生命的绿色药品”已被研究证明具有优效、安全、符合生态等诸多优点,已被越来越多的应用于人类疾病的各个领域。
有关益生乳酸菌在降胆固醇方面的研究,国内外有大量的论文报道和专利成果。CN 104818230A植物乳杆菌(L01)、CN 102899276A嗜热链球菌(BLST)、CN102604851A乳酸乳球菌、CN101559082A乳杆菌(MA2)、CN1186855A尿链球菌(DM891128)及CN 104789488A鼠李糖乳杆菌(SCF 20120718)在降胆固醇的作用中都有一定的效果,但降解率都不高,而戊糖乳杆菌在降胆固醇作用中的专利未见报道,且乳酸菌在降甘油三酯方面的菌株报道鲜见。
【发明内容】
本发明的目的是提供一种具有降胆固醇、降甘油三酯作用的乳酸菌及其应用。
为实现上述目的,本发明的技术方案是:
一种分离自藏獒肠道的乳酸菌,为戊糖乳杆菌(La.Pentosus),菌株已于2013年04月07日保藏于中国微生物菌种保藏管理委员会普通微生物中心,其保藏编号为CGMCC7426,保藏地址为:中国北京市朝阳区北辰西路1号院3号。
本发明通过将藏獒肠道内容物涂布于MRS培养基上进行分离培养,分纯菌株菌落为乳白色,直径约2mm,表面光滑、边缘整齐、中央***,菌落周围有明显的溶钙圈,镜检形态为短杆状,将分纯菌株进行菌株革兰氏染色、平板菌落形态、菌株对蛋黄中胆固醇及胆固醇标准品的降解率、对甘油三酯的降解率、耐酸试验、耐胆盐试验、毒性试验(小鼠)等实验。采用16S rDNA法对所分纯的菌株进行分子鉴定。其16S rDNA序列在NCBI(National Centerfor Biotechnology Information,美国国立生物技术信息中心)数据库中进行比对,结果发现该菌株的基因序列,在所有相似的序列中,与戊糖乳杆菌(La.Pentosus)的同源性为99%,因此结合生理生化特征,鉴定菌株是戊糖乳杆菌,将其命名为EAM-ZL016T。
本发明提供了一种能用于进一步研究开发预防和治疗由于胆固醇甘油三酯过高所引起的心脑血管疾病的功能性食品和保健药品的原料菌株。通过磷硫铁比色法等方法测定菌株EAM-ZT003T的降胆固醇、甘油三酯以及耐酸、耐胆盐效果,并且测定了菌株在小鼠体内是否具有毒副作用。
结果发现:本发明提供的从藏獒肠道中分离纯化出的戊糖乳杆菌(La.Pentosus),具有很好的安全性,且小鼠体内试验发现无毒无害,同时具有良好的胆盐、强酸耐受性,其降胆固醇降甘油三酯能力强,具有抑菌效果,能够应用在功能性食品和保健药品的制备中。所谓功能性食品是指具有特定功能的食品,适宜于特定人群食用,可调节机体的功能,又不以治疗为目的。
【附图说明】
图1为本发明的菌株革兰氏染色结果。
图2为本发明的菌株平板菌落形态。
图3为本发明的菌株对蛋黄中胆固醇及胆固醇标准品的降解率。
图4为本发明的菌株对甘油三酯的降解率。
图5为本发明的菌株耐酸试验结果。
图6为本发明的菌株耐胆盐试验结果。
图7为本发明的菌株对毒性试验小鼠的体重变化。
图8为本发明的菌株毒性试验结果(小鼠肝脏切片)。
图9为本发明的菌株毒性试验结果(小鼠肾脏切片)。
【具体实施方式】
以下结合具体实施例,对本发明进行详细说明。
实施例1
本发明所提供的具有降胆固醇降甘油三酯能力的戊糖乳杆菌EAM-ZL016T的筛选和鉴定。
1菌种的分离、纯化
称取0.5g甘肃玛曲县藏獒肠道内容物,加入到装有4.5ml无菌水的试管中,逐次稀释至10-6,取10-4、10-5、10-6三管稀释液各0.1ml,采用涂布法,涂布于MRS培养基上进行分离,37℃恒温培养48h。挑取菌落,连续划线分离纯化,最后选择单菌落,经镜检确认为纯种后,接种到斜面培养基培养24h后,置4℃冰箱保存备用。
MRS固体培养基的配方及条件为:蛋白胨10g、牛肉膏10g、酵母粉5g、葡萄糖20g、无水乙酸钠5g、吐温-801mL、柠檬酸二胺2g、磷酸氢二钾2g、硫酸镁0.58g、硫酸锰0.25g、碳酸钙20g、琼脂18g、蒸馏水1000mL,pH6.6~6.8,115℃,灭菌20min。
分纯菌株菌落为乳白色,直径约2mm,表面光滑、边缘整齐、中央***,菌落周围有明显的溶钙圈,镜检形态为短杆状,(1-1.2)μm×(1-1.5)μm,单个、成对、短链排列,将分纯菌株命名为EAM-ZL016T。
2菌株生理生化鉴定
将分纯菌株进行革兰氏染色、运动性检查、氧化酶、过氧化氢酶、明胶液化等实验。
菌株革兰氏染色阳性,经半固体培养基穿刺培养发现,菌株沿穿刺线生长,边缘清晰,菌株无运动性,兼性厌氧。菌株不还原硝酸盐,不液化明胶,接触酶和氧化酶反应均为阴性。
表1 EAM-ZL016T生理生化鉴定结果
检测项目 | 结果 | 检测项目 | 结果 | 检测项目 | 结果 | 检测项目 | 结果 |
甘露醇 | + | 乳糖 | + | 硝酸盐(还原) | - | ***醇 | + |
葡萄糖 | + | 七叶苷 | + | 侧金盏花醇 | - | 山梨醇 | - |
棉籽糖 | + | 苯丙氨酸 | + | 胆汁七叶苷 | - | 木糖醇 | + |
麦芽糖 | + | 赤藓醇 | + | 赖氨酸脱羧酶 | - | 苦杏仁苷 | + |
果糖 | + | 松三糖 | + | 鸟氨酸脱羧酶 | - | 酒石酸盐 | - |
淀粉 | - | 蔗糖 | + | 精氨酸脱羧酶 | - | 甘露糖 | + |
硫化氢 | - | 纤维二糖 | + | 精氨酸双水解酶 | - | 密二糖 | + |
醋酸盐 | - | 卫茅醇 | - | β-半乳糖苷 | + | 水杨素 | + |
D-核糖 | + | 肌醇 | - | 甲基红 | + | 鼠李糖 | - |
乙酰胺 | - | ***糖 | - | V.P. | - | 半乳糖 | + |
尿素 | - | 枸橼酸盐 | - | 明胶 | - | 蕈糖 | + |
丙二酸盐 | - | 木糖 | - | 山梨糖 | + | 糊精 | + |
40℃ | - | 15℃ | + | 6.5%NaCl | - | 10%NaCl | - |
316S rDNA分子鉴定
采用16S rDNA法对所分纯的菌株进行分子鉴定。16S rDNA扩增及序列测定由宝生物工程(大连)有限公司完成。
测序完成提交菌株EAM-ZL016T的16S rDNA序列在NCBI(National Center forBiotechnology Information,美国国立生物技术信息中心)数据库中进行比对,结果发现菌株EAM-ZL016T的基因序列,在所有相似的序列中,与戊糖乳杆菌(La.Pentosus)的同源性为99%,因此结合生理生化特征,鉴定菌株EAM-ZL016T是戊糖乳杆菌。该分离自藏獒肠道的戊糖乳杆菌(La.Pentosus),菌株已于2013年04月07日保藏于中国微生物菌种保藏管理委员会普通微生物中心,其保藏编号为CGMCC 7426。
实施例2
本发明所提供的具有降胆固醇降甘油三酯能力的戊糖乳杆菌EAM-ZL016T的降胆固醇效果。
1降蛋黄中胆固醇菌的效果
无菌条件下,于灭菌的培养基中加入一定量鸡蛋黄作为胆固醇源,无菌均匀分装到试管中。以2%(菌体浓度为108cfu/ml)的接种量加入菌液,37℃恒温培养24h,在8000r/min下离心10min,取上清液按照磷硫铁比色法,测定上清液中胆固醇含量。每组实验设定2个重复。
硫磷铁显色剂的配置——三氯化铁溶液:称取5.0g FeCl3·6H2O溶于200ml浓磷酸中;磷硫铁试剂(P-S-Fe试剂):取40ml的三氯化铁溶液用浓硫酸定容到500mL。
磷硫铁比色法:取容量为10ml的离心管,加入4.8ml无水乙醇及0.2ml发酵上清液,置室温内10min后,8000r/min离心5min。另取干净试管,用移液枪准确移取上清液2ml加入试管中,再沿管壁缓慢加入2ml配置好的硫磷铁试剂,立即摇匀后,室温冷却30min。待所生颜色稳定后,用分光光度计在560nm下进行比色,用无水乙醇作空白调零,以未接菌的MRS-蛋黄培养基作对照。
胆固醇降低率按照以下公式计算:
胆固醇降低率=(C-A)/C×100%
A:菌株发酵后培养液在560nm处的OD值
C:对照在560nm处的OD值
经试验测得菌株EAM-ZL016T的降蛋黄中胆固醇能力为64.84%。
2降高纯度胆固醇菌的效果
将菌株以2%(菌体浓度为108cfu/ml)的接种量接种于高胆固醇MRSO-CHOL培养基中,37℃恒温培养24h,在8000r/min下离心10min,取上清液按照磷硫铁比色法,测定上清液中胆固醇含量。用无水乙醇作空白调零,以未接种的高胆固醇MRSO-CHOL培养基作对照。
胆固醇降低率按照以下公式计算:
胆固醇降低率=(C-A)/C×100%
A:菌株发酵后培养液在560nm处的OD值
C:对照在560nm处的OD值
高胆固醇MRSO-CHOL培养基:以1000mL的MRS液体培养基计,含1.0mg/mL胆固醇胶束溶液制备:准确称量胆固醇0.1g放入小烧杯中,加入0.2g牛胆盐、0.1g蔗糖酯、1mL吐温80搅拌均匀,再移取5mL的冰乙酸加热溶解,把溶解液用超声波处理15min后,快速加入到配制好的MRS液体培养基中,边加入边搅拌,使其形成均匀稳定的胶体溶液。
经试验测得菌株EAM-ZL016T的降胆固醇能力为22%。
实施例3
本发明所提供的具有降胆固醇降甘油三酯能力的戊糖乳杆菌EAM-ZL016T的降甘油三酯效果。
无菌条件下,于灭菌的培养基中加入一定量的甘油三酯标准品,无菌分装到试管中。以2%(菌体浓度为108cfu/ml)的接种量加入菌液(未接菌的试管作为空白对照),37℃恒温培养24h,于420nm处测定甘油三酯降解率。
甘油三酯降低率=(C-A)/C×100%
式中的A为菌株发酵后培养液在420nm处的OD值,C为空白对照在420nm处的OD值。
经试验测得菌株EAM-ZL016T的降甘油三酯能力为2.8%。
实施例4
本发明所提供的具有降胆固醇降甘油三酯能力的戊糖乳杆菌EAM-ZL016T的耐酸耐胆盐试验。
1菌株的耐酸试验
将菌株活化后制成菌悬液,采用稀释涂板法测定菌株的浓度。将活化菌株分别接种于pH 6.8、pH 3.0、pH 2.0的MRS液体培养基中,37℃恒温培养10h,利用梯度稀释平板法测定活菌数,做5个平行求平均值。实验结果表明,菌株具有较强的耐酸性,在pH3.0的条件下存活率比较高,pH2.0时,培养10h,菌株的存活率有所下降,但仍能达到106cfu/ml。
2菌株对0.3%胆盐环境的耐受力测定
将菌株活化后制成菌悬液(菌体浓度为108cfu/ml),按2%的接种量分别接种于含0.0%牛胆盐(即空白)、0.3%牛胆盐的复合液体培养基中。37℃培养24h后,分别测定其OD值,做5个平行求平均值,按下述公式计算菌株对胆盐的耐受力。
胆盐耐受力(%)=含胆盐培养基的OD/空白培养基的OD×100%
经试验测得菌株EAM-ZL016T的胆盐耐受能力为15%。人体小肠中胆盐含量在0.03%-0.3%范围内波动,试验所选取胆盐含量为最大浓度。
实施例5
本发明所提供的具有降胆固醇降甘油三酯能力的戊糖乳杆菌EAM-ZL016T的抑菌试验。
分别取活化好的枯草芽孢杆菌、大肠杆菌和金黄色葡萄球菌接种于营养肉汤中,37℃恒温培养24h,用无菌水稀释至108cfu/ml,备用。
将50mL营养琼脂固体培养基灭菌后冷却到45℃,与指示菌(枯草芽孢杆菌、大肠杆菌和金黄色葡萄球菌)新鲜培养物1000μL混匀后倒平板,待平板凝固后放上灭菌的牛津杯。调整菌悬液浓度为108cfu/ml,用移液枪分别量取100μL的菌培养液及无菌水加入牛津杯中,盖上皿盖,将平板置于4℃冰箱扩散,然后放置37℃恒温培养24h,观察小孔周围抑菌圈直径。每个指示菌做两个皿子,测抑菌圈直径,求平均值。结果见表2。
表2戊糖乳杆菌抑菌结果
实施例6
本发明所提供的具有降胆固醇降甘油三酯能力的戊糖乳杆菌EAM-ZL016T的小鼠毒性试验。
将20只小鼠随机分成2组,A组灌胃生理盐水,B组灌胃戊糖乳杆菌悬液。A组小鼠每只每天灌胃生理盐水0.5ml,B组小鼠每只每天灌胃含1×108个戊糖乳杆菌的悬浮液0.5ml。为了保证菌体溶液中一定的活菌数,每次灌胃都采用新鲜处理的菌株。自由进水,每周记录体重。在给药42天后,处死解剖,将心脏、肝脏、脾脏、肾脏、肺取出用生理盐水冲洗并擦拭干净后称重,计算小鼠脏器指数,此外,内脏分离做石蜡切片,观察脏器是否发生病变。实验结果见图7、8、9。
表3毒性试验小鼠脏器指数比较
为期42天的毒性试验发现,小鼠毛色光洁,食欲正常,灌胃42天未出现异常体征,未发现异常死亡,小鼠体重前14天增长较快,后28天趋于稳定,维持在27g左右,但试验过程中未出现消瘦、死亡现象。小鼠解剖后内脏正常,颜色红润、光滑,切片结果显示,小鼠脏器无气质性改变。
结果表明饲喂戊糖乳杆菌EAM-ZL016T对小鼠没有毒副作用。
结论:本发明提供的菌株具有极好的降胆固醇降甘油三酯的功效,并具有非常好的耐酸、耐胆盐性,进入人体胃肠道后,有较多的活菌存在,确保菌株的降胆固醇降甘油三酯活性,菌株具有抑菌效果,在降脂降胆固醇同时,可起到整肠及调节肠道菌群的作用,且菌株没有任何毒副作用。
本发明提供的戊糖乳杆菌EAM-ZL016T的上述特性使其能够应用于制备保健食品和药品中。
最后应说明的是:以上所述仅为本发明的优选实施例而已,并不用于限制本发明,尽管参照前述实施例对本发明进行了详细的说明,对于本领域的技术人员来说,其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分技术特征进行等同替换。凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (2)
1.一种分离自藏獒肠道的戊糖乳杆菌(La.Pentosus),菌株已于2013年04月07日保藏于中国微生物菌种保藏管理委员会普通微生物中心,其保藏编号为CGMCC 7426。
2.权利要求1所述的戊糖乳杆菌在制备降脂降胆固醇功能的食品中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710091198.2A CN107058171B (zh) | 2017-02-20 | 2017-02-20 | 具有降低胆固醇降低甘油三酯作用的戊糖乳杆菌及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710091198.2A CN107058171B (zh) | 2017-02-20 | 2017-02-20 | 具有降低胆固醇降低甘油三酯作用的戊糖乳杆菌及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107058171A CN107058171A (zh) | 2017-08-18 |
CN107058171B true CN107058171B (zh) | 2019-12-20 |
Family
ID=59621755
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710091198.2A Active CN107058171B (zh) | 2017-02-20 | 2017-02-20 | 具有降低胆固醇降低甘油三酯作用的戊糖乳杆菌及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107058171B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107929329B (zh) * | 2017-07-07 | 2023-06-06 | 西北民族大学 | 一种消栓降脂益生复合菌中药颗粒及其制备方法 |
CN109207389B (zh) * | 2017-07-07 | 2023-06-06 | 西北民族大学 | 一种消栓降脂益生复合菌中药口服液及其制备方法 |
WO2020231127A1 (ko) * | 2019-05-14 | 2020-11-19 | 한국식품연구원 | 간 기능 개선 활성을 갖는 균주 및 이의 용도 |
CN115710563A (zh) * | 2022-09-26 | 2023-02-24 | 重庆第二师范学院 | 戊糖乳杆菌cqzc02及其在制备治疗肝损伤药物中的应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103320337A (zh) * | 2012-10-23 | 2013-09-25 | 云南宏斌绿色食品有限公司 | 戊糖乳杆菌 |
CN105969680A (zh) * | 2016-03-23 | 2016-09-28 | 贵州大学 | 一株降胆固醇、降亚硝酸盐的戊糖乳杆菌及其筛选方法 |
-
2017
- 2017-02-20 CN CN201710091198.2A patent/CN107058171B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103320337A (zh) * | 2012-10-23 | 2013-09-25 | 云南宏斌绿色食品有限公司 | 戊糖乳杆菌 |
CN105969680A (zh) * | 2016-03-23 | 2016-09-28 | 贵州大学 | 一株降胆固醇、降亚硝酸盐的戊糖乳杆菌及其筛选方法 |
Non-Patent Citations (1)
Title |
---|
降胆固醇能力强的耐酸耐胆盐乳酸菌的筛选及鉴定;温子辉等;《黑龙江八一农垦大学学报》;20141231;第26卷(第6期);参见全文 * |
Also Published As
Publication number | Publication date |
---|---|
CN107058171A (zh) | 2017-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110272842B (zh) | 一株具有减肥降脂功能的植物乳杆菌lp104 | |
CN110218681B (zh) | 一株发酵乳杆菌kp101及其应用 | |
CN107058171B (zh) | 具有降低胆固醇降低甘油三酯作用的戊糖乳杆菌及应用 | |
CN109679882B (zh) | 一株屎肠球菌dt1-1及其应用 | |
CN113061543B (zh) | 一种植物乳杆菌及其用途 | |
CN112143680B (zh) | 具有抗氧化功效副干酪乳杆菌zjuids05及其应用 | |
CN108707565B (zh) | 一种两歧双歧杆菌及其应用 | |
CN112877262B (zh) | 一种植物乳杆菌及其应用 | |
CN108004155A (zh) | 植物乳杆菌pc-26菌株及其应用 | |
CN106883995A (zh) | 乳酸片球菌jqii-5菌株及其用途 | |
CN112195123B (zh) | 一种植物乳杆菌及其制剂和应用 | |
CN112812999B (zh) | 一株对阴沟肠杆菌具有抑制作用的植物乳杆菌slb01及其衍生产品和应用 | |
CN114231473A (zh) | 一株益生植物乳杆菌及其在低盐发酵肉食品制备中的应用 | |
CN112094785A (zh) | 一种动物双歧杆菌及其制剂与应用 | |
CN115927049A (zh) | 一株长双歧杆菌婴儿亚种b2-01及其应用 | |
CN116445321A (zh) | 降核苷降血尿酸罗伊氏乳杆菌a21160及其应用 | |
CN106754441B (zh) | 具有降低胆固醇、甘油三酯作用的解脂亚罗酵母菌及应用 | |
CN110577907A (zh) | 一种动物双歧杆菌及其应用 | |
CN116970539B (zh) | 一种鼠联合乳杆菌、其组合物及用途 | |
CN117143767B (zh) | 可调节肠道菌群的母乳源发酵粘液乳杆菌msjk0025及其应用 | |
CN116814501B (zh) | 一种缓解肥胖的长双歧杆菌长亚种及其应用 | |
CN104450586A (zh) | 一种干酪乳杆菌及其组合物 | |
CN107929329B (zh) | 一种消栓降脂益生复合菌中药颗粒及其制备方法 | |
CN114317366A (zh) | 菌株及其应用 | |
CN112961808A (zh) | 一种降脂减肥的乳双岐杆菌制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |